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Late onset neurodegenerative diseases represent a major public health concern as the pop-
ulation in many countries ages. Both frequent diseases such as Alzheimer disease (AD,
14% incidence for 80–84 year-old Europeans) or Parkinson disease (PD, 1.4% prevalence
for >55 years old) share, with other low-incidence neurodegenerative pathologies such
as spinocerebellar ataxias (SCAs, 0.01% prevalence) and frontotemporal lobar degenera-
tion (FTLD, 0.02% prevalence), a lack of efficient treatment in spite of important research
efforts. Besides significant progress, studies with animal models have revealed unexpected
complexities in the degenerative process, emphasizing a need to better understand the
underlying pathological mechanisms. Recently, microRNAs (miRNAs), a class of small reg-
ulatory non-coding RNAs, have been implicated in some neurodegenerative diseases.The
current data supporting a role of miRNAs in PD, tauopathies, dominant ataxias, and FTLD
will first be discussed to emphasize the different levels of the pathological processes which
may be affected by miRNAs.To investigate a potential involvement of miRNA dysregulation
in the early stages of these neurodegenerative diseases we have used Drosophila models
for seven diseases (PD, 3 FTLD, 3 dominant ataxias) that recapitulate many features of the
human diseases.We performed deep sequencing of head small RNAs after 3 days of patho-
logical protein expression in the fly head neurons. We found no evidence for a statistically
significant difference in miRNA expression in this early stage of the pathological process.
In addition, we could not identify small non-coding CAG repeat RNAs (sCAG) in polyQ dis-
ease models. Thus our data suggest that transcriptional deregulation of miRNAs or sCAG
is unlikely to play a significant role in the initial stages of neurodegenerative diseases.
Keywords: miRNA, neurodegenerative diseases, ataxia, frontotemporal lobar degeneration, Parkinson disease,
polyQ diseases, deep sequencing
INTRODUCTION
Late onset human neurodegenerative diseases are characterized
by neuronal dysfunction, progressive degeneration, and progres-
sive tissue specific neuronal loss. They include common diseases
such as Alzheimer disease (AD, 14% incidence for 80–84 year-
old Europeans) or Parkinson disease (PD, 1.4% prevalence for
>55 years old), but also a large number of other pathologies pre-
senting lower incidences such as spinocerebellar ataxias (SCAs,
0.01% prevalence) and frontotemporal lobar degeneration (FTLD,
0.02% prevalence). In spite of the large clinical heterogeneity of
these diseases, age is the most prominent risk factor for all of them
(Yankner et al., 2008; Brookmeyer et al., 2011). Consequently, since
the mean age of world population is steadily increasing, they are
becoming a major health concern and economic burden in both
developed and developing countries.
Although, for some of the diseases, sporadic cases are the most
frequent, investigations conducted during the last decades have
identified key genes associated with familial forms. This paved
the way to myriads of studies using either cells or animal mod-
els to understand the physiological basis of these diseases, with
significant success. A common hallmark of several of these aging-
associated neurodegenerative disorders that emerged from these
early studies, is the existence of fibrillar aggregates of aggregation-
prone proteins that may trap other cellular compounds (Jucker and
Walker, 2011). Impairment of protein quality control homeosta-
sis during aging or in response to environmental or endogenous
stresses (notably oxidative stress) may thus contribute to neuronal
dysfunction. However, whether such aggregates or intermediate
forms are toxic or protective is still a matter of debate. Addi-
tionally, animal models have revealed unexpected complexities
in the degenerative process that cannot be reduced to a single
pathological mechanism. Thus, much remains to be learned of
the mechanisms leading to specific neuronal death in late onset
diseases.
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MicroRNAs (miRNAs) have been recently identified as poten-
tial important players in neurodegenerative diseases. miRNAs are
small non-coding RNAs, present in many multicellular organisms
including humans, that post-transcriptionally regulate the expres-
sion of their target genes by inhibition of mRNA translation or
mRNA degradation (Krol et al., 2010). Since miRNAs can simul-
taneously and rapidly target hundreds of genes, it is not surprising
that they have been shown to play an important role in many
developmental processes and in cellular homeostasis (Klooster-
man and Plasterk, 2006; Bushati and Cohen, 2007). Due to these
crucial functions, their activity has to be tightly regulated at many
levels.
Besides minor alternative pathways, the canonical biogenesis
pathway of miRNAs involves (1) the synthesis of a long primary
transcript (pri-miRNA), (2) the cleavage of the pri-miRNA into
a 70–100 nt precursor (pre-miRNA) inside a nuclear multipro-
tein complex called the Microprocessor containing the RNase III
Drosha, (3) the transport of the pre-miRNA into the cytoplasm
where it is cleaved by another RNase III enzyme, Dicer, into a 21–
22 nt long duplex, and (4) the association of one the strands of
the duplex (the active miRNA) with an Argonaute (Ago) protein
within the RISC complex, where it plays its repressive role. Due
to this complex process, the level of expression of a miRNA may
be regulated at several levels. One standard way is through tran-
scriptional regulation of the pri-miRNA synthesis that will impact
the level of miRNA. This accounts for a large part of the com-
plex temporal and spatial regulation of the miRNAs inside the
central nervous system (Kosik, 2006; Kapsimali et al., 2007; Bak
et al., 2008). However, many post-transcriptional mechanisms of
miRNA regulation have also been described (reviewed in; New-
man and Hammond, 2010; Siomi and Siomi, 2010). They involve
either cofactors present inside the Microprocessor complex (Gre-
gory et al., 2004) or RNA-binding proteins that may regulate the
processing of specific subsets of pri-miRNAs, the positive or nega-
tive regulation of pre-miRNA processing by Dicer, and the control
of miRNA turnover.
MicroRNAs have been implicated in neurodegenerative dis-
eases in several ways and can be classified accordingly (reviewed
in; Bushati and Cohen, 2007; Eacker et al., 2009; Gascon and Gao,
2012; Kaur et al., 2012). First, it has been shown in several organ-
isms and in various neuronal subpopulations that disruption of
the miRNA pathway through Dicer depletion impacts neuronal
differentiation and survival (Schaefer et al., 2007; Cuellar et al.,
2008). Similarly, targeted depletion of Dicer in astrocytes, oligo-
dendrocytes, and Schwann cells leads to neurodegeneration (Shin
et al., 2009; Pereira et al., 2010; Tao et al., 2011), pointing out
a potential role of glial miRNAs in neurodegenerative diseases.
Interestingly, lack of Atxn2, the protein involved in SCA2 disease
which interacts with Ago1, impairs the repressive activity of several
miRNAs (McCann et al., 2011). However, it is not known whether
this dysfunction is physiologically relevant to the SCA2 pathology.
Second, several miRNAs (referred to below as class I neu-
rodegenerative disease-associated miRNAs; NDAmiR) have been
shown to target some disease-related proteins and modulate their
cellular concentration. For instance, in AD, several miRNAs are
able to modulate Aβ peptide production through APP or BACE1
targeting, or repress genes implicated in the phosphorylation state
of the Tau protein (reviewed in; Delay et al., 2012). Similarly, sev-
eral miRNAs may target α-synuclein, a protein linked to PD, while
Ataxin-1, the protein implicated in SCA1 disease, is regulated by
at least 4 miRNAs (Gascon and Gao, 2012; and references therein).
However these studies have been conducted in vitro and it is
not currently known whether these regulations are physiologically
important in the course of these diseases.
Finally, recent data suggest that miRNA dysregulation may rep-
resent an important part of pathological mechanisms involved
in neurodegenerative diseases. Dysregulated miRNAs (referred to
below as class II NDAmiR) have several origins. Two proteins
mutated in familial cases of amyotrophic lateral sclerosis (ALS)
or FTLD, the RNA-binding proteins TAR DNA-binding protein-
43 (TDP-43) and fused in sarcoma (FUS), have been identified
in Microprocessor complexes (Gregory et al., 2004; Kawahara and
Mieda-Sato, 2012). Furthermore, TDP-43 also interacts with the
RISC complex and is required for the correct expression of a sub-
set of miRNAs in cell cultures (Kawahara and Mieda-Sato, 2012).
Therefore, some disease-related proteins may directly dysregulate
the expression of some miRNAs (class IIa) through their bio-
genesis pathway. In contrast to these direct evidences, aberrant
expression of miRNAs (class IIb) have been found in a variety of
animal models of neurodegenerative diseases and in post-mortem
brain samples of AD, PD, and Huntington disease (HD) patients
(reviewed in; Lau and de Strooper, 2010; Gascon and Gao, 2012).
In only a few cases potential dysregulation mechanisms could be
proposed. For instance, in the case of HD, inhibition of the REST
co-repressor by the pathological Htt protein likely results in over-
expression of at least four neuronal miRNAs (Johnson et al., 2008;
Packer et al., 2008). However, several caveats may complicate the
interpretation of these data. First, technical issues, such as the sta-
bility of miRNAs during the analysis of brains from patients may
have led to false positive detection (Sethi and Lukiw, 2009). Then,
most studies focused primarily on neuron dysfunctions, and the
relative contribution of neurons and glial cells in miRNA dysreg-
ulation in vivo was not addressed. However, glial inflammatory
responses are observed in many of these diseases and could be
responsible for a significant part of miRNA transcriptome mod-
ifications. Finally, analyses were usually performed at advanced
stages of the diseases where neuronal loss is frequently observed.
The observed differences in miRNA concentration may therefore
arise from differences in tissue composition compared to the con-
trol samples. Alternatively, they may represent unspecific events
consecutive to secondary processes occurring in neurodegenera-
tion such as protein homeostasis perturbations or generation of
oxidative stress. A critical issue is thus to decipher whether miRNA
dysregulation can be observed at the beginning of the pathological
process and, subsequently, play a significant role in the evolution
of the disease.
In this paper we addressed this issue in Drosophila models
related to seven different neurodegenerative diseases (PD, 3 FTLD,
3 dominant ataxias). These models were previously shown to
recapitulate many features of human diseases and are amenable
to subsequent genetic analysis of miRNAs of interest. We used
genetic tools to express pathological proteins specifically in neu-
rons and performed a miRNA profiling by deep sequencing.
We found no evidence for a statistically significant difference in
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miRNA expression in this early stage of the pathological process.
Thus our data suggest that transcriptional deregulation of miR-
NAs is unlikely to play a significant role in the initial stages of
neurodegenerative diseases.
MATERIALS AND METHODS
DROSOPHILA STRAINS AND HUSBANDRY
For SCA models, the following lines were used: UAS-Atxn1-82Q
and UAS-Atxn1-30Q (Fernandez-Funez et al., 2000), UAS-Atxn3-
70Q and UAS-Atxn3-19Q, UAS-Atxn7-102Q and UAS-Atxn7-
10Q (Latouche et al., 2007). The Atxn3 lines were generated
by cloning of the full length Atxn3 coding region described in
(Mueller et al., 2009) inside a pAttB-UAS vector followed by inser-
tion at the Att40 landing site by standard ways. For FTLD diseases
the following transgenic Drosophila strains were used in this study:
UAS-TauV337M (Wittmann et al., 2001); UAS-TDP-43 (Miguel
et al., 2011); and UAS-FUS (Miguel et al., 2012). Drosophila strains
were raised on standard cornmeal-yeast agar medium. Fly cultures
and crosses were carried out at 25˚C.
Males from these strains were crossed with elav-GAL4-
GeneSwitch (ElavGal4GS) females (Osterwalder et al., 2001).
Depending on the protein of interest, more than 500 males or
females (0–2 days old) of the progeny were collected (clusters of
25–30) into food tubes containing standard cornmeal-yeast agar
medium. After 7 days, the flies were transferred to new tubes con-
taining instant Drosophila medium (Carolina Biological Supply
Company, Burlington, NC, USA) or corn yeast medium (SCAs
experiments) with or without RU486 (Mifepristone, Betapharma-
Shanghai Co., Ltd., China) at a final concentration of 1% ethanol
and 200µg/ml RU486. Two days later, the flies were transferred
to new tubes containing fresh media for one more day. After
these 3 days of RU486 induction, flies were quickly frozen in liquid
nitrogen and then stores at−80˚C.
For the PD experiments, the following Drosophila strains were
used: Canton S, w1118, elav-GAL4, UAS-α-synuclein, and UAS-
α-synuclein-A30P (Feany and Bender, 2000). For α-synuclein
expression in neurons, elav-GAL4 virgins were crossed to UAS-α-
synuclein or UAS-α-synuclein-A30P males, or to w1118 for controls.
7 to 10-day-old non-virgin females of the F1 progeny were col-
lected (300–350 flies per genotype) and kept at −80˚C until RNA
extraction.
Paraquat treatment was performed on 7 to 10-day-old Can-
ton S adult females by dietary ingestion. Fifty flies were incubated
at 25˚C in a 8.5 cm diameter Petri dish containing two layers of
Whatman paper soaked with 20 mM paraquat (methyl viologen,
Sigma-Aldrich, St Louis, MO, USA) diluted in 2% (wt/vol) sucrose
or sucrose only for controls. Fourteen similar Petri dishes were
independently treated for each condition. After 24 h, around 300
surviving flies were collected and frozen at−80˚C.
TOTAL RNA ISOLATION
For each head sample, 300 adult fly were freezed in liquid nitrogen
and the heads were recovered by sieving. For each body sample
used in control experiment, 50 flies were freezed in liquid nitro-
gen. These frozen samples were directly transferred into a Lysing
Matrix D tube containing Lysing Matrix beads (Qbiogen) and 1 ml
of qiazol (Qiagen) and grinded with a FastPrep Homogenizer (MP
Biomedicals). The homogenate was incubated at room tempera-
ture for 5 min and then centrifuged at 12,000 g for 10 min at 4˚C to
remove cellular debris. The supernatant was transferred to a fresh
tube, and 200µl of chloroform were added per ml of Qiazol. After
vortex agitation for 30 s, samples were incubated at room tem-
perature for 3 min and then centrifuged at 16,000 g for 15 min at
4˚C. The aqueous phase was transferred to a fresh tube, and RNA
was precipitated by adding 1 volume of isopropanol. Samples were
incubated for 1 h at −20˚C and then centrifuged at 12,000 g for
30 min at 4˚C. The RNA pellet was washed by adding 600µl of
cold 80% ethanol and centrifuged at 16,000 g for 10 min at 4˚C.
The ethanol was then discarded and the pellet air dried for 10 min.
The RNA pellet was dissolved in of Rnase-free water and 250µl
of acid phenol-chlorofom-IAA 125:24:1 (pH 4.5; Ambion) were
added. After vortex agitation for 30 s, samples were centrifuged at
16,000 g for 10 min at 4˚C. The aqueous phase was transferred to
a fresh tube, and 250µl of chloroform were added. After vortex
agitation for 15 s, samples were centrifuged at 16,000 g for 10 min
at 4˚C. The aqueous phase was transferred to a fresh tube, and 1/10
volume of NaAc (3M, pH 5.0) and 4 volumes of cold 100% ethanol
were added. Samples were then incubated overnight at−20˚C for
RNAs precipitation and centrifuged at 16,000 g for 30 min at 4˚C.
The RNA pellet was washed with 600µl of cold 80% ethanol and
centrifuged at 16,000 g for 10 min at 4˚C. After a second wash step
and centrifugation, the RNA pellet was air dried for 10 min and in
50µl of RNA-free water. Before being further processed, the con-
centration of RNA samples was measured by spectrophotometry
and their quality was checked with an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, USA).
DEEP SEQUENCING AND DATA ANALYSIS
Small RNAs from fly head RNAs were cloned using the using the
TruSeq (TM) SBS v5 Kit and sequenced using an Illumina Hi-
Seq 2000 at Fasteris (http://www.fasteris.com/). Sequence reads
in fastq format were trimmed from the adapter sequence 5′-
CTGTAGGCACCATCAAT-3′ and reads with more than 18 nt were
matched to the Drosophila melanogaster genome release 5.43 using
Bowtie and allowing 0 or 1 mismatch (-v1 option). Matched
reads were then re-matched against (1) the miRBase r18 miRNA
stem-loop sequences. Reads matching these sequences with 0
or 1 mismatch were retained for subsequent analysis whereas
unmatched reads were re-matched to (2) other non-coding RNA
sequences (tRNAs, rRNAs, and miscellaneous ncRNAs). Reads
matching these sequences with 0 or 1 mismatch were counted
whereas unmatched reads were re-matched to (3) transposon ele-
ment sequences. This procedure was further iteratively applied to
(4) introns, (5) mRNAs, and (6) intergenic sequences to produce
the annotations in Table 1.
Using the miRNA_bowtie_profiler python script (available
upon request), we parsed the bowtie output files to count and map
the miRNA reads to the miRNA stem-loop sequences. To assign
read counts to either the 5p or 3p miRNAs, each miRNA stem-loop
sequence was iteratively split between −20 and +20 nucleotides
relative to the middle of the miRNA stem-loop sequence. For
each split position, the numbers of reads mapping entirely to the
upstream and downstream substrings were computed and stored,
whereas reads mapping across the split position were discarded.
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Table 1 | miRNAs implicated in neurodegenerative diseases belonging to conserved miRNA families with Drosophila members.
Identified miR Family_ID Family_name dme-miR Disease Reference Variation
hsa-let-7b MIPF0000002 let-7 dme-let-7 AD Wang et al. (2011) Down
hsa-let-7c MIPF0000002 let-7 dme-let-7 AD Wang et al. (2011) Down
hsa-let-7e MIPF0000002 let-7 dme-let-7 AD Wang et al. (2011) Up
hsa-let-7g MIPF0000002 let-7 dme-let-7 AD Schonrock et al. (2010) Down
hsa-let-7g MIPF0000002 let-7 dme-let-7 AD Wang et al. (2011) Down
hsa-let-7i MIPF0000002 let-7 dme-let-7 AD Schonrock et al. (2010) Down
hsa-let-7i MIPF0000002 let-7 dme-let-7 AD Wang et al. (2011) Down
hsa-miR-98 MIPF0000002 let-7 dme-let-7 AD Wang et al. (2011) Down
mmu-let-7b MIPF0000002 let-7 dme-let-7 AD Wang et al. (2009) Up
mmu-let-7d MIPF0000002 let-7 dme-let-7 AD Wang et al. (2009) Up
mmu-let-7e MIPF0000002 let-7 dme-let-7 AD Wang et al. (2009) Up
mmu-mir-98 MIPF0000002 let-7 dme-let-7 AD Wang et al. (2009) Up
cel-let-7 MIPF0000002 let-7 dme-let-7 PD Asikainen et al. (2010) Down
dme-let-7 MIPF0000002 let-7 dme-let-7 PD Gehrke et al. (2010) NC
hsa-let-7c MIPF0000002 let-7 dme-let-7 PolyQ-HD Martí et al. (2010) Down
hsa-let-7d MIPF0000002 let-7 dme-let-7 PolyQ-HD Martí et al. (2010) Down
hsa-let-7e MIPF0000002 let-7 dme-let-7 PolyQ-HD Martí et al. (2010) Down
hsa-let-7g MIPF0000002 let-7 dme-let-7 PolyQ-HD Martí et al. (2010) Up
hsa-let-7i MIPF0000002 let-7 dme-let-7 PolyQ-HD Martí et al. (2010) Up
hsa-miR-98 MIPF0000002 let-7 dme-let-7 PolyQ-HD Martí et al. (2010) Down
hsa-miR-98 MIPF0000002 let-7 dme-let-7 PolyQ-HD Martí et al. (2010) Up
cel-miR-1 MIPF0000038 mir-1 dme-mir-1 PD Asikainen et al. (2010) Down
hsa-miR-99a MIPF0000025 mir-99 dme-mir-100 AD Wang et al. (2011) Down
hsa-miR-99b MIPF0000025 mir-99 dme-mir-100 AD Wang et al. (2011) Down
hsa-miR-100 MIPF0000025 mir-99 dme-mir-100 PolyQ-HD Martí et al. (2010) Up
hsa-miR-99a MIPF0000025 mir-99 dme-mir-100 PolyQ-HD Martí et al. (2010) Up
hsa-miR-99b MIPF0000025 mir-99 dme-mir-100 PolyQ-HD Martí et al. (2010) Up
mmu-mir-125a MIPF0000017 mir-125 dme-mir-125 AD Wang et al. (2009) Up
hsa-miR-133b MIPF0000029 mir-133 dme-mir-133 PD Kim et al. (2007) Down
hsa-miR-137 MIPF0000106 mir-137 dme-mir-137 AD Geekiyanage and Chan (2011) Down
mmu-miR-137 MIPF0000106 mir-137 dme-mir-137 AD Schonrock et al. (2010) Down
hsa-miR-137 MIPF0000106 mir-137 dme-mir-137 PolyQ-HD Martí et al. (2010) Down
hsa-mir-137 MIPF0000106 mir-137 dme-mir-137 Tauopathies Smith et al. (2011) NC
hsa-miR-184 MIPF0000059 mir-184 dme-mir-184 AD Wang et al. (2011) Up
hsa-miR-184 MIPF0000059 mir-184 dme-mir-184 PolyQ-HD Martí et al. (2010) Down
hsa-miR-193b MIPF0000082 mir-193 dme-mir-193 AD Wang et al. (2011) Down
hsa-miR-193b MIPF0000082 mir-193 dme-mir-193 PolyQ-HD Martí et al. (2010) Up
hsa-miR-210 MIPF0000086 mir-210 dme-mir-210 AD Hebert et al. (2008) Down
hsa-miR-210 MIPF0000086 mir-210 dme-mir-210 PolyQ-HD Martí et al. (2010) Up
hsa-mir-29a MIPF0000009 mir-29 dme-mir-285 AD Geekiyanage and Chan (2011) Down
hsa-miR-29a MIPF0000009 mir-29 dme-mir-285 AD Shioya et al. (2010) Down
hsa-miR-29a MIPF0000009 mir-29 dme-mir-285 AD Wang et al. (2011) Down
hsa-miR-29b-1 MIPF0000009 mir-29 dme-mir-285 AD Hebert et al. (2008) Down
hsa-miR-29c MIPF0000009 mir-29 dme-mir-285 AD Wang et al. (2011) Down
mmu-mir-29a MIPF0000009 mir-29 dme-mir-285 AD Wang et al. (2009) Down
mmu-mir-29c MIPF0000009 mir-29 dme-mir-285 AD Wang et al. (2009) Down
hsa-mir-29a MIPF0000009 mir-29 dme-mir-285 PolyQ-HD Johnson et al. (2008) Up
hsa-miR-29c MIPF0000009 mir-29 dme-mir-285 PolyQ-HD Martí et al. (2010) Down
hsa-miR-29c MIPF0000009 mir-29 dme-mir-285 PolyQ-HD Martí et al. (2010) Up
mmu-mir-29a MIPF0000009 mir-29 dme-mir-285 PolyQ-HD Johnson et al. (2008) Down
mmu-miR-29c MIPF0000009 mir-29 dme-mir-285 PolyQ-HD Lee et al. (2008) Down
(Continued)
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Table 1 | Continued
Identified miR Family_ID Family_name dme-miR Disease Reference Variation
hsa-miR-33a MIPF0000070 mir-33 dme-mir-33 AD Wang et al. (2011) Down
hsa-miR-33a MIPF0000070 mir-33 dme-mir-33 PolyQ-HD Martí et al. (2010) Up
hsa-miR-33b MIPF0000070 mir-33 dme-mir-33 PolyQ-HD Martí et al. (2010) Up
hsa-miR-34a MIPF0000039 mir-34 dme-mir-34 AD Lukiw and Alexandrov (2012) Up
hsa-miR-34a MIPF0000039 mir-34 dme-mir-34 AD Wang et al. (2011) Down
hsa-miR-34b MIPF0000039 mir-34 dme-mir-34 AD Wang et al. (2011) Down
mmu-mir-34a MIPF0000039 mir-34 dme-mir-34 AD Wang et al. (2009) Up
hsa-miR-34b MIPF0000039 mir-34 dme-mir-34 PD Minones-Moyano et al. (2011) Down
hsa-miR-34c MIPF0000039 mir-34 dme-mir-34 PD Minones-Moyano et al. (2011) Down
hsa-miR-375 MIPF0000114 mir-375 dme-mir-375 PolyQ-HD Martí et al. (2010) Down
hsa-miR-25 MIPF0000013 mir-25 dme-mir-92a AD Lukiw and Alexandrov (2012) Up
hsa-miR-92b MIPF0000013 mir-25 dme-mir-92a AD Wang et al. (2011) Down
mmu-mir-92b MIPF0000013 mir-25 dme-mir-92a AD Wang et al. (2009) Up
hsa-miR-25 MIPF0000013 mir-25 dme-mir-92a PolyQ-HD Martí et al. (2010) Up
hsa-miR-25 MIPF0000013 mir-25 dme-mir-92b AD Lukiw and Alexandrov (2012) Up
hsa-miR-92b MIPF0000013 mir-25 dme-mir-92b AD Wang et al. (2011) Down
mmu-mir-92b MIPF0000013 mir-25 dme-mir-92b AD Wang et al. (2009) Up
hsa-miR-25 MIPF0000013 mir-25 dme-mir-92b PolyQ-HD Martí et al. (2010) Up
Then, the split position for which the sum of the upstream and
downstream reads was the nearest of the total number of reads
mapped to the miRNA stem-loop sequence was retained, and the
upstream and downstream read counts were assigned to the 5p
and 3p miRNAs, respectively. Using this algorithm, miRNA5p and
miRNA3p read counts were unambiguously assigned, indepen-
dently of miRBase annotations for miRNA and miRNA∗ species.
Note that in the case of non-canonical miRNAs with reads tilled
across the stem-loop precursor, the procedure leads to arbitrarily
assign read counts to miRNA5p and miRNA3p species which may
not be biologically relevant; however, these counts still reflect the
expression level of the miRNA stem-loop precursor.
Expression profiling of mature miRNAs was performed using
the hit tables generated as described above and the DEseq R
package (Anders and Huber, 2010). The recently improved ver-
sion (1.7.6) was used, with the default options (notably sharing
Mode=“maximum” in the estimate Dispersions function).
WESTERN BLOTTING
Fifty adult fly heads were dissected and homogenized in 100µl
RIPA buffer [50 mM Tris-HCl, pH 8, 150 mM NaCl, 20 mM
EDTA, 1% Nonidet-P40 (v/v), 50 mM natrium fluoride, 20 mM
N -ethylmaleimide, and a cocktail of protease inhibitors from
Sigma-Aldrich, St. Louis, MO, USA]. Samples were placed under
agitation at 4˚C for 1 h and then centrifuged at 11,300 g for 20 min
at 4˚C to remove cellular debris. Protein concentrations in RIPA
fraction were measured using the DC Protein Assay Kit (Bio-Rad
Laboratories, Hercules, CA, USA). Protein samples were loaded
in SDS-PAGE sample buffer (240 mM Tris-HCl, pH 6.8, 6% SDS,
30% glycerol, 0.06% bromophenol blue) and resolved by a 10%
SDS-PAGE. Proteins were transferred to nitrocellulose membranes
(Hybond C-Extra; Amersham Biosciences, Arlington Heights, IL,
USA). The following antibodies were used in this study: rab-
bit polyclonal anti-TARDBP/TDP-43 (1:5,000; Proteintech Group,
Inc., Chicago, IL, USA) and rat monoclonal anti-elav (1:100,
Developmental Studies Hybridoma Bank, Iowa City, IA, USA).
Membranes were incubated with peroxidase-labeled anti-rat or
anti-rabbit antibodies (1:10,000) from Jackson Immunoresearch
Laboratories (WestGrove, PA, USA), and signals were detected
with chemiluminescence reagents (GE Healthcare, Saclay, France).
Signals were acquired with a GBOX (Syngene, Cambridge, UK)
monitored by the Gene Snap software.
REAL-TIME QUANTITATIVE RT–PCR
For each genotype, 1µg of total RNA were first treated with
Deoxyribonuclease I Amplification Grade (Sigma-Aldrich) and
then reverse-transcribed into cDNA, using the First Strand cDNA
Synthesis Kit (Amersham Biosciences). PCR reactions were per-
formed in a final volume of 20µl, using the SsoFast Eva-
green Supermix (Bio-Rad, Hercules, CA, USA) with primers
at a final concentration of 300 nM (primer sequences available
upon request). PCR amplifications were performed on a CFX96
Real-Time System (Bio-Rad) using the following cycling steps:
enzyme activation at 98˚C for 2 min; denaturation and anneal-
ing/extension respectively at 98˚C for 10 s and 60˚C for 15 s (40
cycles). The comparative−∆∆Ct method was then used to deter-
mine quantitative values for gene expression levels in each sample
using 14.3.3ε and Cyp1 as normalizer genes.
RESULTS
GENERATION OF miRNA PROFILES AT EARLY DISEASE STAGES IN
DROSOPHILAMODELS
Among the miRNAs that have been proposed to be involved
in neurodegenerative diseases in mammals, 30 of them belongs
to a conserved miRNA family that has at least one member in
Drosophila (Table 1). Surprisingly, we noticed in many cases oppo-
site directions of transcriptional changes inside a given family
and a given pathology. This points out the need of additional
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studies to uncover the functional significance of these observa-
tions, and, notably, to investigate whether miRNA dysregulation
can be observed at the first stages of the diseases. Therefore our
major aim was to focus on class II NDAmiR in Drosophila models
of human neurodegenerative diseases that have been well char-
acterized previously and amenable to early stage study. Thus we
used dominant models of ataxias (SCA1, SCA3, SCA7) and FTLD
(TDP-43, FUS, TAU) where pathological or control proteins can
be targeted to neurons in a temporally controlled manner with the
RU486 inducible ElavGal4GS line (see below for complete geno-
type description). Importantly, since its first introduction in 2007
by one of us to modelize successfully SCA7 pathology (Latouche
et al., 2007), the elavGS system has been used by several labs to
study Drosophila neurodegenerative disease models. This includes
a model for Aβ induced pathology (Sofola et al., 2010; Rogers
et al., 2012), models for polyQ diseases (Spinobulbar muscular
atrophy (SBMA; Pandey et al., 2007), and SCA3 (Martin-Lannerée
et al., 2006), model for Parkinson disease (Kanao et al., 2010) as
well as the two FTD models used in this study (FUS and TBP43;
Lanson et al., 2011; Miguel et al., 2011, 2012). Therefore, it is
now widely accepted that inducible elavGS models are adequate
to express disease proteins in adult CNS with pathological conse-
quences that mimic the disease. Flies were induced when 7 day-old,
by incorporation of RU486 into their food, and RNA extraction
was performed on 10 day-old fly heads. As expected from pre-
vious characterization of the GeneSwitch system (Osterwalder
et al., 2001), proteins are readily detected 24 h after induction
(Figure 1A). Thus, with this strategy, we are able to detect early
transcriptome changes occurring during the first 3 days of the
pathological process.
In addition to these dominant models, we used a model of spo-
radic PD where flies were treated during 2 days with the neurotoxic
compound paraquat before RNA extraction on fly heads. We com-
pleted this study with another model of PD linked to α-synuclein
overexpression. In all these cases the age of the flies selected
for RNA extraction was 7 days. Therefore they were analyzed
separately from the previous batch of samples.
Following RNA extraction and quality control, generation, and
sequencing of small RNA libraries were performed on Illumina
Hi-Seq. A total of 266 million reads were generated for the 36
samples of this study and were matched to different mutually
exclusive categories (miRNAs, tRNAs, ncRNAs, miscRNAs, trans-
posons, Introns, transcripts, and intergenic sequences). A detailed
description for each sample is given in Table S1 in Supplementary
Material. As a whole, as expected, the miRNAs class is the most
abundant (61% of the total; Figure 2). With these selected reads,
normalization between samples and subsequent statistical analysis
were performed with Deseq (Anders and Huber, 2010), a state of
the art software that models the null distribution of the count data
with negative binomial distribution and evoluted variance. After
normalization, we expected the miRNA counts to be highly cor-
related between samples corresponding to uninduced conditions
(RU0) where the pathological proteins are not induced. This was
indeed the case as illustrated in Figure 3 for samples issued from
SCAs experiment. Therefore we could gain in statistical power by
implementing, in the Deseq analysis, an additional set of reference
data composed of independent samples corresponding to all the
FIGURE 1 | (A) Fast induced expression of TDP-43 in adult Drosophila
neurons. Western blot analyses on total protein extracts prepared from
heads of ElavGal4GS flies in which expression of the human transgene was
induced with 200 ng/µl of RU486 for 1, 2, or 3 days. Control flies:
ElavGal4GS/+. elav is used as a loading control. TDP-43 proteins are readily
detected 24 h after induction and the level of expression remains stable. (B)
Toxicity of full length expanded ATXN3. Longevity of ElavGal4GS/
UAS-ATXN3-Q70 flies was measured in conditions of neuronal protein
induction (200µg/ml of RU486 into food medium) or without induction (no
RU486). Mean lifespan is significantly reduced from 51 to 35.3 days (69%)
when the expanded protein is expressed. As already shown, expression of
an unexpanded ATXN3-Q19 protein does not modify the lifespan. (C)
Toxicity of full length expanded ATXN1. Longevity of
ElavGal4GS/UAS-ATXN1-Q82 flies was measured in conditions of neuronal
protein induction (200µg/ml of RU486 into food medium) or without
induction (no RU486). Mean lifespan is significantly reduced from 45 to
28 days (62%) when the expanded protein is expressed.
RU0 and other control conditions. This improved the accuracy
of variance calculation and thus provides reduced p-values in the
analysis. It also take into account the natural variation of miRNA
expression in non-pathological flies of different genotypes, which
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should be distinguished to pathology related variations. How-
ever it should be emphasized that this procedure only improves
the estimation of variation between samples of the same biologi-
cal conditions and that, in all cases, comparisons and differential
expression analysis are performed between flies of similar geno-
types (induced or not induced) to eliminate genetic background
variations. Results presented below have been obtained with this
FIGURE 2 | Distribution of RNA reads. 266 million reads were generated
for the 36 samples of this study. They were matched to the different
mutually exclusive categories, according to the procedure described in the
Section “Material and Methods”: miRNAs, tRNAs, ncRNAs, miscRNAs,
transposons, Introns, transcripts, and intergenic sequences. The
distribution of the reads for each class is indicated on the graph.
optimized method, although standard analysis (using one to one
condition comparison) provides similar conclusions.
To validate our method of analysis we took advantage of
the differences of miRNA expression observed in the differ-
ent body parts. We performed deep-seq analysis on whole
body of age matched flies, combined this data with our head
control samples and used our pipeline to identify differen-
tially expressed genes in the head. The raw and normalized
counts of the miRNAs species are provided in Table S2 Sup-
plementary Material. With our data, we identified 106 sta-
tistically significantly (p< 0.01) differentially expressed miR-
NAs, shared between 33 head enriched miRNAs (with ratios
0.08<WholeBody/Head< 0.58) and 73 head depleted miRNAs
(with ratios 1.66<WholeBody/Head< infinite). Since similar
datasets have been generated in two independent studies (Chung
et al., 2008; Berezikov et al., 2011; accession numbers GSM286601,
GSM286602, GSM322543, GSM399107) for the modENCODE
project, we could compare our WholeBody/Head ratios with these
two datasets. We observed a striking correlation between these
three independent experiments with 96 out of our 106 differ-
entially expressed miRNAs (91%) being confirmed by the mod-
ENCODE data (Figure 4 and Table S2 Supplementary Material).
This suggests that our procedure may distinguish differentially
expressed miRNAs with high reliability.
The full lists of raw and normalized counts of the 480
Drosophila miRNAs species are provided in Table S3 Supplemen-
tary Material for the different conditions corresponding to our
neurodegenerative models.
miRNA PROFILING IN SCAs MODELS
Transgenic lines used for SCA1 and SCA7 models (UAS-Atxn1-
15Q, UAS-Atxn1-82Q, UAS-Atxn7-10Q, UAS-Atxn7-102Q) have
been described and characterized earlier (Fernandez-Funez et al.,
2000; Latouche et al., 2007). For SCA3 models we generated
two new full length Atxn3 transgenic lines derived from con-
structs described in (Mueller et al., 2009), UAS-Atxn3-15Q and
FIGURE 3 | Correlation between normalized reads. Distribution of
miRNAs read counts was compared between the median distribution
of all the control samples and the different distributions. A typical
correlation distribution is presented in (A) for the ATXN1-82Q RU0
sample. In (B) the distribution of the correlation coefficients for curves
similar to (A) are displayed for all the ATXN samples of our first
sequencing run. Notice that all except one values range above 0.99,
reflecting the high correlation between samples. Sample identification:
1: ATXN3-70Q-0, 2: ATXN3-70Q-200, 3: ATXN3-19Q-0, 4:
ATXN3-19Q-200, 5: ATXN1-82Q-0, 6: ATXN1-82Q-200, 7: ATXN1-30Q-0,
8: ATXN1-30Q-200, 9: ATXN7-102Q-0, 10: ATXN7-102Q-200, 11:
ATXN7-10Q-0, 12: ATXN7-10Q-200.
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FIGURE 4 | Comparisons of miRNA enrichment or depletion in male
fly heads. Comparisons of ratios of normalized miRNAs read counts in fly
bodies or heads were performed with 3 independent data sets: Exp1 (this
study), Exp2 (Chung et al., 2008), Exp3 (Berezikov et al., 2011). We
identified 106 statistically differentially expressed miRNAs in our analysis
(Exp1 dataset). High correlations between Exp1 and Exp2 (diamonds) or
Exp3 (squares) ratios for these miRNAs are observed. Notice that since
decapitated flies were used to generate body extracts in Exp2 and 3, this
results in lower Nbody/Nhead ratios for head enriched miRNAs compared
to Exp1.
UAS-Atxn3-70Q. We checked that, similarly to expanded trun-
cated form of Atxn3, expression of the pathological form in
adult neurons of elavGal4GS/+; UAS-Atxn3-70Q flies reduced
their lifespan (Figure 1B). These flies present also a progres-
sive decline in climbing performance with a climbing index of
50% of control flies at 23 days and 14% at 30 days. In the same
way, expression of the pathological form of ATXN1 in adult neu-
rons of elavGal4GS/+; UAS-Atxn1-82Q flies reduced their lifespan
(Figure 1C).
Importantly, all these SCAs related proteins have been impli-
cated in transcription regulation. Atxn1 and Atxn7 are present in
transcription complexes (Helmlinger et al., 2006; Lam et al., 2006)
and Atxn3 binds to chromatin and may regulate gene expression
by interacting with histone acetylases (Evert et al., 2006). There-
fore these proteins are good candidates for a direct regulation
of miRNA expression. We profiled miRNAs in two independent
samples of total RNA extracted for heads of flies expressing the
expanded Atxn proteins and 1 sample for uninduced control
flies or flies expressing the normal allele, and performed multiple
comparisons of expression with the Deseq software in standard
mode. miRNAs presenting fold change greater than 1.5 between
expanded protein expressing flies (RU200) and control flies (RU0)
are given in Table S3 Supplementary Material. We noticed that
many of these selected miRNAs present low expression values or,
in some cases, high variability of expression between replicated
samples or between the set of control samples. Consequently, in
any case, we found no statistically significant difference (p< 0.01)
in miRNA expression. This suggests that toxicity in the SCAs
model in Drosophila is not related to misexpression of miRNAs
mediated by the expanded Atxn proteins in the early stages of the
disease. However, when we looked more closely to the miRNAs
from Table 1 corresponding to conserved miRNA families, we
noticed a trend to overexpression of mir-33 and mir-92a in all
ataxia models (Table 2), although the statistical significance is
below threshold in independent analysis. Closer analysis of these
miRNAs at different time points coupled with functional analysis
are under progress.
Recently a study in HD models identified 21 nt small CAG
repeats RNAs (sCAG) as potential mediators of expanded Htt
toxicity (Bañez-Coronel et al., 2012). Thus, in addition from miR-
NAs profiling, we searched for such species in our in vivo polyQ
disease models by mapping all the sequences obtained in one
model against the transgene used in this model. In all SCA dis-
eases models we were unable to identify an increase in sCAG
(Table 3). Indeed, only two perfect match reads of 18 and 21
nucleotides are detected in the ATXN7-102Q sample, while three
and two imperfect match reads are detected in the ATXN1-82Q
and ATXN3-70Q samples respectively. Thus, HD may present a
specific toxicity mechanism compared to SCAs diseases, although
alternative hypothesis discussed in the last section may explain our
result.
miRNA PROFILING IN FTLD MODELS
Most cases of FTLD are characterized by the abnormal accu-
mulation of either the microtubule-associated protein Tau, the
transactive response DNA-binding protein-43 (TDP-43) or the
FUS protein. TDP-43 proteins have been shown to facilitate
the post-transcriptional processing of a subset of miRNAs not
only in the nucleus but also in the cytoplasm (Kawahara and
Mieda-Sato, 2012). This sequential facilitation was achieved both
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Table 3 | No siRNAs like sequences are generated from CAG repeats.
Sample Coordinate
polyQ
Orientation Position Sequence N mismatch
or insertion
Size
READS MAPPING INTOTRANSGENES
ATXN1-82Q 1236–1482 + 1274 GCATCAGCATCAGCAGCA 2 18
ATXN1-82Q 1237–1482 – 1324 AGCAGCAGCAGCAACAG 1 17
ATXN1-82Q 1238–1482 + 1347 CAGCAGCATCAGCAGCA 1 17
ATXN3-70Q 1374–1584 + 1517 GCAGCATCAGCAACA 2 15
ATXN3-70Q 1375–1584 + 1561 AGCAGCAGCCGGAGCAGCAGC 2 21
ATXN7-102Q 735–1041 + 779 GCAGCAGCAGCAGCAGCA 0 18
ATXN7-102Q 735–1041 + 809 GCAGCAGCAGCAGCAGCAGCA 0 21
ATXN7-102Q 735–1041 + 821 ACAGCAGCAGCAGCAGCA 1 18
ATXN7-102Q 735–1041 + 952 AGCAGCAGCATCAGCA 1 16
ATXN7-102Q 735–1041 + 976 AGCAGCAGCAGCGGCA 1 16
ATXN7-102Q 735–1041 + 988 AGCATCAGCAGCAGCA 1 16
ATXN7-102Q 735–1041 + 1015 AGCAACAGCAGCAGCA 1 16
ATXN7-102Q 735–1041 – 1028 GGAGCAGCAGCAGCCG 2 16
ATXN1-82Q ATXN3-70Q ATXN7-102Q
N total reads
N reads in transgene 751 1472 1632
N reads in repeat 3 2 8
N reads in repeat-PM 0 0 2
Reads/kb in transgene 107 199 225
Reads/kb in repeat 12 10 26
The small RNA libraries from the three expanded Atxn protein samples were mapped with Bowtie to the sequence of the corresponding transgene, to identify
potential sequences generated from the CAG repeats. All the sequence identified as mapping into the repeat region are depicted here. Notice that the sizes of these
sequences do not match with the 21 nt size expected for an siRNA and that most of them present some mismatches, which casts some doubt on their origin. In
addition, as shown in the bottomTab, we did not observe an increase of small RNA production in the repeat region, but, in contrast, a decrease compared to the rest
of the transgene sequences.
by the direct binding of TDP-43 to the primary and precur-
sor forms of the miRNAs and by a protein–protein interaction
between TDP-43 and the nuclear Drosha and cytoplasmic Dicer
complexes. FUS proteins have also been involved in the Drosha
complex, but the role of these proteins in miRNA processing
has not been elucidated so far (Gregory et al., 2004). Therefore
TDP-43 and FUS are good candidates for a direct regulation
of miRNA expression. Expression of wild-type form of TDP-43
or FUS proteins was achieved using transgenic Drosophila lines
(UAS-TDP-43, UAS-FUS) previously described and characterized
(Miguel et al., 2011, 2012). miRNA expression profiling was per-
formed in two independent samples of total RNA extracted from
heads of flies expressing (RU200) or not (RU0) TDP-43 or FUS
proteins. As shown in Table S3 Supplementary Material, simi-
larly to SCAs models, miRNAs presenting fold change greater
than 1.5 between induced and uninduced flies presented low
expression values and/or high variability of expression between
replicated samples or between the set of control samples, lead-
ing to none statistically significant difference (p< 0.01) in miRNA
expression.
Concerning Tau proteins, it has been shown that suppres-
sion of miRNA maturation enhances Tau-mediated cell death in
flies, indicating a protective role of miRNA in Tau neurotoxic-
ity (Bilen et al., 2006). Furthermore, genetic ablation of Dicer
in mice results in disease-like changes in endogenous Tau phos-
phorylation and neurodegeneration (Hébert et al., 2010). How-
ever there is no direct indication of miRNA dysregulations in
flies expressing Tau. Transgenic lines used for FTLD-Tau model
(UAS-TauV337M) have been described and characterized previ-
ously (Wittmann et al., 2001). In human, the V337M mutation
had originally been described in a family (the Seattle family A)
presenting an FTLD. Due to the X chromosomal insertion of the
transgene, this particular set of experiments was performed using
Drosophila females instead of males. A new set of control sam-
ples, corresponding to uninduced UAS-TauV337M/+; elavGS/+
samples (RU0); and elavGS/+ samples (RU0 and RU200), was
therefore designed. Again, profiling of miRNA expression in
two independent samples showed that miRNAs presenting fold
change greater than 1.5 between induced and uninduced flies
presented low expression values and/or high variability of expres-
sion between replicated samples or between the set of con-
trol samples, leading to none statistically significant difference
(p< 0.01) in miRNA expression. However, like in ataxia mod-
els, mir-92a present trend to overexpression in all FTD models
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(Table 2), although the statistical significance is below threshold
in independent analysis.
miRNA PROFILING IN PD MODELS
We analyzed potential miRNA misregulation in two condi-
tions that mimic Parkinson’s disease in flies. First, we treated
the flies with paraquat, a toxicant suspected to be a factor
of neurodegeneration in PD (Tanner et al., 2011) that is fre-
quently used in animals to model PD (Cannon and Greenamyre,
2010). Paraquat produces free radicals in cells, which leads to
dopamine neuron dysfunction and degeneration in Drosophila
(Chaudhuri et al., 2007). Flies were treated with 20 mM paraquat
for one-day, a dose that we found induces death of about
half of the flies. Second, we used a transgenic model orig-
inally described by (Feany and Bender, 2000), in which the
PD-implicated human protein α-synuclein or its more path-
ogenic mutant form α-synuclein-A30P were expressed in all
Drosophila neurons starting from early stages of development.
In this α-synuclein model, pathological features that include
locomotor impairments and dopamine neuron loss only arise
after 3 weeks of adult life (Feany and Bender, 2000). We per-
formed our study on 7 to 10-day-old flies to detect potential
early effects of α-synuclein neuronal accumulation on miRNA
transcription.
As shown in Table S3 Supplementary Material we did not
identified any statistically significant change in all the conditions
analyzed. For instance, in the paraquat experiment, although mean
fold changes between paraquat treated flies and control flies greater
than two were observed rather frequently, they usually resulted
from fluctuations in one of the four samples not confirmed in the
other replicate. Compared to SCAs and FTLD studies where 100%
flies are alive at the time of RNA extraction, higher variations in
read counts may have resulted from greater heterogeneity in flies
submitted to paraquat treatment that were recovered at the 50%
survival time.
DISCUSSION
In this study, we investigated in several Drosophila models of neu-
rodegenerative diseases whether miRNA misexpression may be
observed after expression of toxic proteins (SCAs, FTLD, genetic
PD) or toxic treatment (sporadic PD). In contrast to other pro-
filing studies in model organisms or in humans, we measured
miRNA expression at an early stage of the pathological process
(3 days after toxic protein induction or treatment), in an attempt to
uncover early transcriptional dysregulations linked to the diseases.
However, no statistical significant variations in miRNA expression
were observed in any of the cases.
Many studies previously reported differences in some miRNA
expression in worm and mice models of AD, HD, PD or in post-
mortem patient brain samples. In the latter case, a potential draw-
back of miRNA profiling is the limited stability and relatively short
half-life (1–3.5 h) of some miRNAs (especially those with AT-TA
content). Indeed, brain samples of post-mortem intervals (PMI)
greater than 4 h and as high as 27 h hours (Martí et al., 2010) have
been used in some studies, which may lead to overstated conclu-
sions. Noticeably, miRNAs found differentially expressed in some
of these studies (Martí et al., 2010; Wang et al., 2011) present
higher percentages of AT-TA content (11%) than the complete
miRNA collection (9%). Therefore, as already suggested by Sethi
and Lukiw (2009), much care should be brought to sample collec-
tions and only experiments using samples with PMI< 2 h should
be considered for future analysis and comparisons with animal
models.
This potential problem of miRNA stability does not usually
exist for analysis of samples from animal models (including our
study) where fast freezing of tissues is performed. Thus, in addi-
tion to the reliable human data from low PMI samples, the reports
of differential expression of miRNAs in worm and mice mod-
els for AD, HD, and PD are at odds with our findings, since
they suggest that miRNA dysregulation is a common feature
of neurodegenerative diseases. However, a significant difference
with our study focused on the earliest stages of the patholog-
ical processes, is that miRNA profiling has been usually per-
formed in aged animals where the pathological features are already
present.
Since most of the diseases analyzed in our study with Drosophila
models (SCAs, FTLDs) have not been submitted to similar miRNA
profiling in mouse models, we cannot exclude the lack of miRNA
dysregulation in these pathologies. Alternatively, the lack of sig-
nificant miRNA dysregulation in our study may reflect the pro-
gressivity of the diseases. In this view the earliest stages following
expression of a pathological protein would not be associated to
changes in miRNA transcriptome while, at subsequent stages,
some miRNAs would be dysregulated. Secondary events such as
inflammation processes could play an important role in these lat-
ter steps. In agreement to this scheme miRNA-146a, a cytokine
responsive miRNA, is induced in late stages of AD mouse mod-
els but not in younger animals (Li et al., 2011). Importantly, in
contrast to miRNA, mRNA misregulation may be observed at
early stages in at least some of our models. We and others have
already documented early transcriptome changes as early as 12 h
of paraquat treatment (Zou et al., 2000; Girardot et al., 2004).
In addition, after completion of our study, one of us used the
same RNA samples to perform mRNA deep-seq analysis on the 3
FTP models. Between 69 and 327 mRNAs were misregulated on
these models, Although the description of this work is outside the
scope of this paper, we confirmed here the induction of 5 chap-
erones by qRT-PCR analysis in the TauV337M model (Table 4).
This shows that mRNA misregulation can occur 72 h after the
pathological protein induction in at least four models used in this
study.
In terms of potential therapeutic strategies it is important
to elucidate whether miRNAs are early or late players in the
neurodegenerative pathological processes. Therefore subsequent
profiling experiments at different time points in the various
animal models available are required to address this issue. In
the case of Drosophila models particular attention should be
brought to the two members of conserved mir family, mir-33,
and mir-92a, that show trend toward overexpression in some
models, albeit not statistically significant at this early time point.
Notice, however, that, in these kinetic studies, conducted at
the latter stages of the diseases, the issue of changes in tissue
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Table 4 | Examples of deep sequencing analysis of mRNA species and validation by RT-qPCR.
Gene id Count A Count A′ Count B Count B′ Mean A Mean B Deep-seq
fold change
padj RT-qPCR
fold change*
RT-qPCR
fold change‡
DnaJ-1 1923 1697 2211 2891 1799 2530 1.41 2.4E-05 1.33 1.37
Hsp83 14887 13143 17140 22448 13939 19636 1.41 1.9E-05 1.22 1.26
Hsp68 483 430 497 945 452 718 1.59 3.0E-08 1.64 1.70
Hsp70Bc 110 95 164 393 101 277 2.73 1.7E-31 1.32 1.37
Hsp70Aa 342 247 663 1301 292 966 3.31 9.1E-61 1.50 1.57
A: ElavGal4GS/+ RU200 #1; A′:ElavGal4GS/+ RU200 #2; B:ElavGal4GS/TauV337M RU200 #1; B′:ElavGal4GS/TauV337M RU200 #2.
*: normalizer gene 14.3.3 ε; ‡: normalizer gene Cyp1.
The 2 RU-induced FTLD-Tau samples and the 2 RU-induced female controls were submitted to deep sequencing of the mRNA species and analyzed as described
previously. As a result, we observed that the 3 days-induced expression of Tau in Drosophila adult neurons induced a statistically significant misregulation of several
genes among them heat-shock proteins for which we performed a validation by RT-qPCR, confirming the overexpression of these genes in the early stages of the
disease. Fold changes in the two types of quantification are indicated in bold.
composition must be taken into account to avoid misleading
interpretations.
As mentioned earlier, TDP-43 and FUS have been described
as Drosha-associated protein. Furthermore, TDP-43 has been
implicated in the production of a subset of precursor miR-
NAs (pre-miRNAs; Kawahara and Mieda-Sato, 2012) and its
knockdown in culture cells can affect selected microRNA lev-
els (Buratti et al., 2010). Strikingly, in this study we reported
that TDP-43 or FUS overexpression for 3 days in adult differ-
entiated neurons do not result in statistically significant dif-
ference in miRNA expression, indicating that an increase of
the steady-state level of TDP-43 or FUS proteins in vivo do
not modify the activity of Drosha complex 72 h after protein
induction.
In addition to the miRNA profiling, we also analyzed for
three polyQ disease models the generation of small (CAG)n
RNAs. Surprisingly, we did not identify such species in our mod-
els. This contrast with the recent identification of 21 nt CAG
repeat RNAs (sCAG) in cellular and mouse HD models that
have been proposed to be mediators of expanded Htt toxicity
(Bañez-Coronel et al., 2012). Although the sCAG may be spe-
cific to HD and related to the existence of an antisense transcript
generated from a weak promoter (Chung et al., 2011), it is notice-
able that untranslated long CAG repeats are toxic in mouse (Hsu
et al., 2011), worm (Wang et al., 2011), and fly (Li et al., 2008).
Therefore generation of toxic sCAG may be a general phenom-
enon in these species, relevant to all polyQ diseases. However,
our result demonstrates unambiguously that these sCAG species
are either not generated in young flies or are quickly eliminated.
We suspect that age related changes may disrupt cellular home-
ostasis and lead to the progressive appearance of these toxic
species. In vivo kinetics experiments are scheduled to check this
hypothesis.
FINAL REMARK
The role of miRNAs in neurodegenerative diseases is still elusive
in spite of an increasing number of reports. Importantly, most
of these diseases are progressive and develop at old age. As our
data suggest that miRNAs and sCAG may not be significantly
involved in the early stages of these diseases, it urges for new
longitudinal studies and genetic manipulations on animal mod-
els to better understand whether a progressive disruption of the
production of these small RNA species may be truly relevant to
neurodegenerative diseases.
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sheet. A comparison of the fold changes between miRNA levels in bodies and
heads in the three experiments is provided in the third sheet. The 106 miRNAs
identified as statistically differentially expressed in our study are
highlighted.
Table S3 | Number of read counts without normalization (“raw data”
sheet) or normalized (“norm data” sheet) for all the miRNA species
identified in the samples of this study. MirBase r18 was used for read
assignment as indicated in the Section “Material and Methods”.
Table S4 | Results of statistical analysis with Deseq. For each of the
comparisons analyzed for SCAs, FTLD, and PD models, the miRNAs with fold
changes greater than two or lower than 0.5 are provided with the probability
value for significant change calculated before (p-value) or after (padj)
adjustement for multiple testing using the Benjamini–Hochberg (BH) method.
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are given, in addition to the absolute values of the samples.
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